TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29229652

Group type: EXPERIMENTAL
Intervention: Individualised treatment by general practitioners based on pathophysiological phenotyping and individualised treatment goals.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualised lifestyle intervention (web-based and face-to-face) to improve daily physical activity and dietary changes.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control cohort receiving routine clinical care.
Number of subjects: 0
Study: 26625119

Group type: EXPERIMENTAL
Intervention: Type of cycle path
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Traffic density
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Environmental maintenance
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Evenness of cycle path
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Speed limits
Number of subjects: 1232
Study: 23196855

Group type: EXPERIMENTAL
Intervention: CT-guided group with overlay of 3D CS images on live fluoroscopy
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CT-guided group
Number of subjects: 17
Study: 21722028

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention for DBD
Number of subjects: 84

Group type: COMPARATOR
Intervention: Healthy comparison (HC) group
Number of subjects: 84
Study: 19537014

Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 35
Study: 16966110

Group type: EXPERIMENTAL
Intervention: Acupuncture (three outpatient treatments with eight needles applied to bilateral points LI4, SP6, UB31, and UB32)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual medical care (control group)
Number of subjects: 56
Study: 15277739

Group type: EXPERIMENTAL
Intervention: Cerivastatin (C)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pravastatin (P)
Number of subjects: 36
Study: 10755175

Group type: EXPERIMENTAL
Intervention: Auditory integration training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 16
Study: 8774286

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg three times per day for > or = 3 days)
Number of subjects: 6
Study: 1595317

Group type: EXPERIMENTAL
Intervention: Collagen fleece (Lyostypt)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gelatine sponge (Marbagelan)
Number of subjects: 100
Study: 6086765

Group type: EXPERIMENTAL
Intervention: Topical acyclovir
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 31178203

Group type: EXPERIMENTAL
Intervention: da Vinci SP robotic system
Number of subjects: 21
Study: 29905758

Group type: EXPERIMENTAL
Intervention: SSU hospitalisation
Number of subjects: 430

Group type: COMPARATOR
Intervention: IMD hospitalisation
Number of subjects: 430
Study: 26281857

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Group Therapy (ACT-G)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 126
Study: 24911421

Group type: EXPERIMENTAL
Intervention: Problem-solving intervention (PSI) consisting of 2 home visits and 18 telephone calls over a 3-month intensive intervention and a 9-month maintenance period. Both groups received monthly information letters in addition to usual care.
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group receiving usual care and monthly information letters.
Number of subjects: 122
Study: 22048466

Group type: EXPERIMENTAL
Intervention: varenicline
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: bupropion
Number of subjects: 1175
Study: 19851115

Group type: EXPERIMENTAL
Intervention: elvitegravir/r (150/100 mg once daily) plus maraviroc (150 mg twice daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: maraviroc (150 mg twice daily) before or after elvitegravir/r (150/100 mg once daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: elvitegravir/r (150/100 mg once daily)
Number of subjects: 36
Study: 18021205

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: TCA 33% solution
Number of subjects: 25
Study: 16027889

Group type: EXPERIMENTAL
Intervention: Cell therapy (cell suspension from immature nervous and hemopoietic tissues injected into the subarachnoidal space)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cell therapy
Number of subjects: 30
Study: 12370107

Group type: EXPERIMENTAL
Intervention: 2.5 mg finasteride/day
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 5 mg finasteride/day
Number of subjects: 56
Study: 10999118

Group type: EXPERIMENTAL
Intervention: Preoperative percutaneous transhepatic biliary drainage (PTBD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 40
Study: 7672841

Group type: EXPERIMENTAL
Intervention: IMZ implants
Number of subjects: 392

Group type: COMPARATOR
Intervention: Periotest method
Number of subjects: 392
Study: 1315825

Group type: EXPERIMENTAL
Intervention: Candoxatril 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Candoxatril 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Candoxatril 200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3881331

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Presence of cirrhosis and HBeAg
Number of subjects: 20
Study: 31306313

Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Educational handout
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control
Number of subjects: 256
Study: 28799232

Group type: EXPERIMENTAL
Intervention: Professionally administered plaque removal (PAPR) and photodynamic therapy (PDT)
Number of subjects: 20
Study: 27618939

Group type: EXPERIMENTAL
Intervention: Healthy Pregnancy project (intervention group)
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Common practice (control group)
Number of subjects: 1509
Study: 23917169

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSMZ 17648 (Pylopass™)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 22136942

Group type: EXPERIMENTAL
Intervention: Social contact with a depressed individual during psychiatric practical (N=127)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Compulsory psychiatry practical alone (Control group, N=98)
Number of subjects: 127
Study: 19803579

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy (3 individual sessions)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Counseling as usual (3 individual sessions)
Number of subjects: 405
Study: 17080375

Group type: EXPERIMENTAL
Intervention: Gauze bandage
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Occlusive bandage with gauze lining
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Foam bandage
Number of subjects: 102

Group type: COMPARATOR
Intervention: All bandage types
Number of subjects: 102
Study: 15132405

Group type: COMPARATOR
Intervention: Stepper machine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Skier machine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 14
Study: 11709252

Group type: EXPERIMENTAL
Intervention: Noncontact tonometry
Number of subjects: 60

Group type: COMPARATOR
Intervention: Goldmann applanation tonometry
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of noncontact and applanation methods
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 60
Study: 9118750

Group type: EXPERIMENTAL
Intervention: Colonic pouch anastomosis
Number of subjects: 46

Group type: COMPARATOR
Intervention: Straight anastomosis
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 8243858

Group type: EXPERIMENTAL
Intervention: Simvastatin (10‐20 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 18
Study: 3896661

Group type: EXPERIMENTAL
Intervention: Single dose of 10% clotrimazole cream
Number of subjects: 111

Group type: COMPARATOR
Intervention: Twice-daily application of 2% clotrimazole cream for 3 days
Number of subjects: 111
Study: 30171345

Group type: EXPERIMENTAL
Intervention: High viscosity glass ionomer cement (GIC)
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Compomer (COM)
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Glass carbomer (CAR)
Number of subjects: 568

Group type: COMPARATOR
Intervention: Comparison between GIC and COM
Number of subjects: 568

Group type: COMPARATOR
Intervention: Comparison of CAR with GIC and COM
Number of subjects: 568
Study: 29797150

Group type: EXPERIMENTAL
Intervention: Child and Adolescent Services Assessment (CASA)
Number of subjects: 72
Study: 27768727

Group type: EXPERIMENTAL
Intervention: 8 mM supplemental alanyl-glutamine (AlaGln) added to glucose-based PD fluid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional acidic, single chamber 3.86% glucose PD fluid without AlaGln
Number of subjects: 20
Study: 25031188

Group type: EXPERIMENTAL
Intervention: Low-dose thiazide diuretics (12.5 mg/day of hydrochlorothiazide)
Number of subjects: 1130

Group type: COMPARATOR
Intervention: No thiazide diuretics
Number of subjects: 1130
Study: 23147291

Group type: EXPERIMENTAL
Intervention: Recombinant human bone morphogenetic protein-2 (rhBMP-2) with resorbable collagen sponge
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Autologous iliac crest bone grafting
Number of subjects: 18

Group type: COMPARATOR
Intervention: Periosteoplasty
Number of subjects: 18
Study: 20127616

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (10 Hz, 10 sessions, 10,000 stimuli over 2 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 32
Study: 18570306

Group type: EXPERIMENTAL
Intervention: DUAL 1500 (1500 mg R1626 bid + peginterferon alfa‐2a)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: DUAL 3000 (3000 mg R1626 bid + peginterferon alfa‐2a)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: TRIPLE 1500 (1500 mg R1626 bid + peginterferon alfa‐2a + ribavirin)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard of Care (SOC: peginterferon alfa‐2a + ribavirin)
Number of subjects: 104
Study: 16029797

Group type: EXPERIMENTAL
Intervention: 2.5 Gy fraction (total dose 15.0 Gy)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: 5.0 Gy fraction (total dose 30.0 Gy)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Overall locoregional recurrence rate
Number of subjects: 290
Study: 11925390

Group type: EXPERIMENTAL
Intervention: Thyrotrophin-releasing hormone (TRH) infusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Dopaminergic type 2 (DA2) receptor blockade
Number of subjects: 21

Group type: COMPARATOR
Intervention: Comparison with fertile patients without endometriosis
Number of subjects: 21
Study: 10521386

Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids
Number of subjects: 52
Study: 9150976

Group type: EXPERIMENTAL
Intervention: Pallesthesiometry (vibration sensitivity threshold measurement)
Number of subjects: 0
Study: 2205571

Group type: EXPERIMENTAL
Intervention: Xylocaine (1 mg/kg iv)
Number of subjects: 30
Study: 7430412

Group type: EXPERIMENTAL
Intervention: Erythromycin estolate capsules
Number of subjects: 16

Group type: COMPARATOR
Intervention: Enteric-coated erythromycin base tablets
Number of subjects: 16
Study: 31164360

Group type: EXPERIMENTAL
Intervention: Loaded self-managed exercise intervention including education and advice on physical activity
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 20
Study: 28232972

Group type: EXPERIMENTAL
Intervention: Staged toothbrush (Candida Parodin)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: V-shaped toothbrush (Oral-B Ortho)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Planar control brushes (Paro M 43)
Number of subjects: 35
Study: 26005776

Group type: EXPERIMENTAL
Intervention: Simvastatin (20mg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Atorvastatin (20mg/day)
Number of subjects: 46
Study: 23942231

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Family-focused therapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Enhanced relapse prevention
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caregiver group psychoeducation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Brief technique-driven interventions
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (specific study)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Enhanced relapse prevention (specific study)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Brief technique-driven interventions (specific study)
Number of subjects: 9
Study: 21336838

Group type: EXPERIMENTAL
Intervention: CHO mouth rinse (25 ml)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA) mouth rinse
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CHO mouth rinse
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both tests (1-RM and strength endurance)
Number of subjects: 12
Study: 19058194

Group type: EXPERIMENTAL
Intervention: Continuous training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interval training
Number of subjects: 0
Study: 17192510

Group type: EXPERIMENTAL
Intervention: Innovator 0.005% latanoprost ophthalmic solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclodextrin-containing latanoprost ophthalmic solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 0
Study: 15149259

Group type: EXPERIMENTAL
Intervention: Intergroup competition (combination of competition and cooperation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Competition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cooperation
Number of subjects: 0
Study: 11464717

Group type: EXPERIMENTAL
Intervention: TNF-alpha levels in sera of ALS patients
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CD2, CD4, CD8 markers on mononuclear cells
Number of subjects: 15
Study: 9727375

Group type: EXPERIMENTAL
Intervention: ACE I/D and PstI genotypes in patients with overt proteinuria or chronic renal failure (127 patients)
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: ACE I/D and PstI genotypes in patients with microalbuminuria (335 patients)
Number of subjects: 941

Group type: COMPARATOR
Intervention: ACE I/D and PstI genotypes in normoalbuminuric patients (254 patients)
Number of subjects: 941
Study: 7979809

Group type: EXPERIMENTAL
Intervention: Cryopreservation-thawing of sperm from patients with teratozoospermia
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cryopreservation-thawing of sperm from fertile donors
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Frozen-thawed-washed specimens
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fresh sperm samples from patients
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fresh sperm samples from donors
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis for patient group
Number of subjects: 27
Study: 2730278

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (mCPP) administered intravenously
Number of subjects: 22
Study: 31559634

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 155 U every 12 weeks for 3 cycles
Number of subjects: 282

Group type: COMPARATOR
Intervention: Topiramate 50-100 mg/day to week 36
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 282

Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 282
Study: 28703838

Group type: EXPERIMENTAL
Intervention: Revifast® with DCI/MI
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: DCI/MI alone
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 110
Study: 25344375

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 mcg/d, N=80)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo (N=78)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 158
Study: 25226738

Group type: EXPERIMENTAL
Intervention: Natural honey (70 g daily for 4 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (same diet without honey)
Number of subjects: 70
Study: 20934312

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (Hcort)
Number of subjects: 20
Study: 18817597

Group type: EXPERIMENTAL
Intervention: Supervised treatment (10 mg amodiaquine/kg and 4 mg artesunate/kg daily for 3 days, directly observed in hospital)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Unsupervised treatment (first dose supervised, remaining doses taken at home)
Number of subjects: 308
Study: 16839800

Group type: EXPERIMENTAL
Intervention: Exercise intervention with manipulation
Number of subjects: 131

Group type: COMPARATOR
Intervention: Exercise intervention without manipulation
Number of subjects: 131
Study: 12870136

Group type: EXPERIMENTAL
Intervention: Intensive surveillance strategy (periodic clinical examinations, laboratory tests, radiographic imaging, CEA testing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less frequent testing
Number of subjects: 0
Study: 10747828

Group type: EXPERIMENTAL
Intervention: trovafloxacin 200 mg od
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ciprofloxacin 500 mg bd
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: lomefloxacin 400 mg od
Number of subjects: 48
Study: 8694169

Group type: EXPERIMENTAL
Intervention: Topical ibuprofen
Number of subjects: 10

Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1893812

Group type: EXPERIMENTAL
Intervention: verapamil 80 mg orally every 6 hr for 10 doses
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: diltiazem 60 mg by mouth as one dose
Number of subjects: 10

Group type: COMPARATOR
Intervention: no premedication
Number of subjects: 10
Study: 7065521

Group type: EXPERIMENTAL
Intervention: High serum concentration of theophylline (20 mg/L)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low serum concentration of theophylline (10 mg/L)
Number of subjects: 20
Study: 31249362

Group type: EXPERIMENTAL
Intervention: FLG loss-of-function mutations
Number of subjects: 712
Study: 28353600

Group type: EXPERIMENTAL
Intervention: Gum-chewing (sugarless gum, 3 times daily for at least 15 minutes until postoperative exhaust defecation)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (No gum)
Number of subjects: 75
Study: 26535950

Group type: EXPERIMENTAL
Intervention: Family Check-Up intervention
Number of subjects: 731

Group type: COMPARATOR
Intervention: Women, Infants, and Children as usual
Number of subjects: 731
Study: 23789741

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 48
Study: 21184653

Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19656025

Group type: EXPERIMENTAL
Intervention: Full-mouth ultrasonic debridement + amoxicillin and metronidazole
Number of subjects: 25

Group type: COMPARATOR
Intervention: Full-mouth ultrasonic debridement + placebo
Number of subjects: 25
Study: 18042574

Group type: EXPERIMENTAL
Intervention: Low vision rehabilitation program
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 126
Study: 14739186

Group type: EXPERIMENTAL
Intervention: Recombinant follicle stimulating hormone
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Electrocautery followed by clomiphene citrate and recombinant follicle stimulating hormone
Number of subjects: 168

Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 168
Study: 11152843

Group type: EXPERIMENTAL
Intervention: Peak exercise systolic blood pressure < or =140 mm Hg
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Exercise program participation
Number of subjects: 625
Study: 9129894

Group type: EXPERIMENTAL
Intervention: 15,000 IU of heparin (group A)
Number of subjects: 400

Group type: COMPARATOR
Intervention: 100 IU.kg‐1 of heparin (group B)
Number of subjects: 400
Study: 7961027

Group type: EXPERIMENTAL
Intervention: Thermoradiotherapy (HTRT) with regional hyperthermia and radiotherapy, total dose ranged from 42 to 80 Gy (mean 62.9 Gy) for definitive treatment, and 38 to 47 Gy (mean 40.6 Gy) for preoperative cases. Radiofrequency capacitive hyperthermia was administered twice weekly, with total sessions ranging from 5 to 16 (mean 9.0) for definitive treatment and 3 to 8 (mean 6.7) for preoperative cases.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (RT) with historical data, initially unresectable Stage III NSCLC irradiated definitively with 50 Gy or more (26 cases), or became resectable after radiotherapy and operated (4 cases).
Number of subjects: 19
Study: 2885365

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Astemizole + Alcohol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine + Alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study: 31959233

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise programme for 12 weeks
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity group (LPAG) aiming to increase daily physical activity and reduce sedentary behaviour for 12 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise programme
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity group (LPAG)
Number of subjects: 51
Study: 29358714

Group type: EXPERIMENTAL
Intervention: Disulfiram treatment in AD model mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disulfiram treatment in SH-SY5Y human neuronal cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disulfiram treatment in alcohol-dependent patients
Number of subjects: 0
Study: 27741244

Group type: EXPERIMENTAL
Intervention: Text message support program
Number of subjects: 710